Behandlingen med Busilvex i den anbefalede dosis og ifølge behandlingsplanen bevirker omfattende myelosuppression hos alle patienter.
The consequence of treatment with Busilvex at the recommended dose and schedule is profound myelosuppression, occurring in all patients.